About Silo Pharma, Inc.
https://silopharma.comSilo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems.
CEO
Eric Weisblum
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-09-19 | Reverse | 1:50 |
| 2022-09-15 | Reverse | 1:50 |
ETFs Holding This Stock
Summary
Showing Top 2 of 2
Ratings Snapshot
Rating : C+
Price Target
Institutional Ownership
ANSON FUNDS MANAGEMENT LP
Shares:952.38K
Value:$373.05K
ADVISORSHARES INVESTMENTS LLC
Shares:364.88K
Value:$142.92K
VIRTU FINANCIAL LLC
Shares:107.79K
Value:$42.22K
Summary
Showing Top 3 of 15
About Silo Pharma, Inc.
https://silopharma.comSilo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $18.02K | $918.73K ▼ | $-1.11M ▲ | -6.16K% ▲ | $-0.12 ▲ | $-1.11M ▲ |
| Q2-2025 | $18.02K ▼ | $1.27M ▲ | $-1.2M ▼ | -6.68K% ▼ | $-0.19 ▲ | $-1.2M ▼ |
| Q1-2025 | $18.03K | $1.11M ▼ | $-1.03M ▲ | -5.72K% ▲ | $-0.23 ▲ | $-1.03M ▲ |
| Q4-2024 | $18.03K ▲ | $1.5M ▲ | $-1.73M ▼ | -9.6K% ▼ | $-0.39 ▼ | $-1.79M ▼ |
| Q3-2024 | $18.02K | $1.03M | $-928.81K | -5.15K% | $-0.22 | $-924.64K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $5.94M ▼ | $6.38M ▼ | $1.38M ▼ | $5.01M ▲ |
| Q2-2025 | $6.26M ▲ | $6.65M ▲ | $1.74M ▼ | $4.92M ▲ |
| Q1-2025 | $5.45M ▼ | $5.9M ▼ | $1.89M ▼ | $4.01M ▼ |
| Q4-2024 | $7.08M ▼ | $7.41M ▼ | $2.38M ▲ | $5.03M ▼ |
| Q3-2024 | $8.02M | $8.57M | $1.78M | $6.78M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-1.11M ▼ | $-955.49K ▲ | $-95.47K ▼ | $634.92K ▼ | $-416.05K ▼ | $-955.49K ▲ |
| Q2-2025 | $1.03M ▲ | $-1.29M ▲ | $388.1K ▼ | $2.09M ▲ | $1.2M ▲ | $-1.29M ▲ |
| Q1-2025 | $-1.03M ▲ | $-1.64M ▼ | $871.38K ▲ | $0 | $-768.92K ▲ | $-1.64M ▼ |
| Q4-2024 | $-1.73M ▼ | $-917.43K ▲ | $-37.66K ▲ | $0 ▼ | $-955.09K ▼ | $-917.43K ▲ |
| Q3-2024 | $-928.81K | $-1.35M | $-40.43K | $1.74M | $354.59K | $-1.35M |
CEO
Eric Weisblum
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-09-19 | Reverse | 1:50 |
| 2022-09-15 | Reverse | 1:50 |
ETFs Holding This Stock
Summary
Showing Top 2 of 2
Ratings Snapshot
Rating : C+
Price Target
Institutional Ownership
ANSON FUNDS MANAGEMENT LP
Shares:952.38K
Value:$373.05K
ADVISORSHARES INVESTMENTS LLC
Shares:364.88K
Value:$142.92K
VIRTU FINANCIAL LLC
Shares:107.79K
Value:$42.22K
Summary
Showing Top 3 of 15